Extavia Articles
European neurologists expect significant increases in the use of both Tysabri and Extavia in their multiple sclerosis patients
24 December 2010
Neurologists eagerly await new oral treatment options for MS, such as EMD Serono's Movectro and Novartis' Gilenia
27 April 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
Novartis Multiple sclerosis drug Extavia cleared by US FDA
17 August 2009
Correction: Novartis' Extavia
9 June 2008
Approval for Novartis' generic Betaferon in EU
2 June 2008
Showing 1-7 of 7 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
